Alterity Therapeutics (ATHE) Receivables - Accured (2020 - 2026)
Alterity Therapeutics (ATHE) posted Receivables - Accured of $85709.0 for Q2 2026, down 97.3% on a QoQ basis from $3.2 million in Q2 2021.
Powered by 
Analysis
Alterity Therapeutics (ATHE) Receivables - Accured (2020 - 2026) Analysis & Trends
Alterity Therapeutics has reported Receivables - Accured for 3 years, with the latest figure at $85709.0 in Q2 2026.
- On a quarterly basis, Receivables - Accured changed N/A year-over-year to $85709.0 in Q2 2026; TTM through Jun 2026 was $85709.0, a N/A change from a year earlier, with the FY2026 full-year figure at $85709.0, changed N/A from the prior year.
- Receivables - Accured was $85709.0 for Q2 2026 at Alterity Therapeutics, down from $3.2 million in the prior quarter.
- The five-year high for Receivables - Accured was $85709.0 in Q2 2026, with the low at $85709.0 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 21.60 Mn |
| 10 | Alterity Therapeutics | 72.80 Mn | 72.80 Mn | - | 85,709.03 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 85,709.03 |
| Jun 30, 2021 | 3.18 Mn |
| Dec 31, 2020 | 3.83 Bn |
| Jun 30, 2020 | 8,247.81 |